Minerva Neurosciences (NASDAQ:NERV) Given Neutral Rating at HC Wainwright

Minerva Neurosciences (NASDAQ:NERV)‘s stock had its “neutral” rating reiterated by HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $5.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 179.33% from the stock’s current price.

Separately, StockNews.com assumed coverage on Minerva Neurosciences in a report on Saturday. They issued a “sell” rating for the company.

Minerva Neurosciences Price Performance

Shares of Minerva Neurosciences stock opened at $1.79 on Wednesday. Minerva Neurosciences has a one year low of $1.71 and a one year high of $7.53. The business’s 50 day simple moving average is $2.17 and its two-hundred day simple moving average is $2.40. The stock has a market capitalization of $12.52 million, a P/E ratio of -4.07 and a beta of 0.12.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.49. Sell-side analysts expect that Minerva Neurosciences will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC lifted its position in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 25,764 shares of the biopharmaceutical company’s stock after acquiring an additional 8,525 shares during the period. Citadel Advisors LLC owned 0.37% of Minerva Neurosciences worth $57,000 as of its most recent SEC filing. Institutional investors and hedge funds own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.